drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (biologic)
drug_description
Autologous ex vivo–expanded tumor-infiltrating lymphocyte (TIL) cell therapy enriched for tumor-reactive T cells; mediates anti-tumor activity via TCR recognition and cytotoxic mechanisms (perforin/granzyme) with cytokine secretion.
nci_thesaurus_concept_id
C200139
nci_thesaurus_definition
A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patients resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs GT201 specifically recognize and kill the patients tumor cells.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous ex vivo–expanded tumor-infiltrating T cells that retain native TCRs to recognize patient-specific tumor antigens and mediate anti-tumor effects via cytotoxic granule release (perforin/granzyme) and cytokine secretion, leading to direct tumor-cell killing and immune amplification.
drug_name
GT201
nct_id_drug_ref
NCT05724732